© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 10, 744,
May 16, 2001
© 2001 Oxford University Press
NEWS |
Awards, Appointments, Announcements
Marc R. Blackman, M.D., has been appointed the first clinical director of the new Division of Intramural Research of the National Center for Complementary and Alternative Medicine, a component of the National Institutes of Health.Blackman assumed his duties in April. Prior to coming to NIH, he was professor of medicine at the Johns Hopkins University School of Medicine and chief of the Division of Endocrinology and Metabolism at the Johns Hopkins Bayview Medical Center, where he was also program director of the NIH-funded General Clinical Research Center.
Brawley Appointed
Otis Brawley, M.D., has joined Emory University School of Medicine, Atlanta, as professor of medicine and oncology and the Emory Rollins School of Public Health as professor of epidemiology.
Brawley also has been named chief of the Solid Tumor Service at the Winship Cancer Institute at Emory University.
Prior to Emory, Brawley was assistant director at the National Cancer Institute for its Office of Special Populations Research. He held an appointment in the Division of Cancer Prevention and was an attending physician at Bethesda Naval Hospital and the National Institutes of Health Clinical Center.
Kramer Named
Barnett Kramer, M.D., has been named associate director for disease prevention of the National Institutes of Health.
Kramer replaced William Harlan, M.D., who retired April 30.
Kramer will retain his current position as director of the NIH Office of Medical Applications of Research. He is also editor in chief of the Journal of the National Cancer Institute.
Fellows Elected
Stanley B. Kaye, M.D., and Peter Boyle, Ph.D., have been elected fellows of the Royal Society of Edinburgh.
Kaye is the Cancer Research Campaign Professor of Medical Oncology at the Royal Marsden Hospital in Sutton, England. Boyle is director of the Division of Epidemiology and Biostatistics at the European Institute of Oncology in Milan, Italy, and chairman of prevention and control at the Imperial Cancer Research Fund in the United Kingdom.
The Royal Society of Edinburgh comprises fellows from the spectrum of academic disciplines, including professional, technical, and business interests.
Schold Appointed
S. Clifford Schold, M.D., has been appointed chief medical officer of the University of Pittsburgh Medical Center Health System’s Pittsburgh Clinical Research Network.
The network will serve as a single point of entry into the health system for industry sponsors of clinical trials.
Schold is director of the Neuro-Onocology Program at the University of Pittsburgh Cancer Institute and assistant vice chancellor for clinical research.
Wood Appointed
Richard D. Wood, Ph.D., has been appointed the Richard M. Cyert Chair in Molecular Oncology and director of the molecular and cellular oncology program at the University of Pittsburgh Cancer Institute.
The Cyert chair was established in 1997 and is funded by a $1.5 million grant. Wood comes to the University of Pittsburgh from the Imperial Cancer Research Fund in the United Kingdom, where he was a principal scientist and honorary professor in the department of biochemistry and molecular biology at University College in London.
Vanderbilt Designated
The National Cancer Institute has designated the Vanderbilt-Ingram Cancer Center, Nashville, as a Comprehensive Cancer Center.
Vanderbilt-Ingram Cancer Center is affiliated with Vanderbilt University and Medical Center. It includes the Henry-Joyce Cancer Clinic, inpatient facilities in Vanderbilt Hospital and Children’s Hospital, and the region’s first comprehensive breast diagnostic center and its only Cancer Pain and Symptom Management Program and Family Cancer Risk Service.
Board Expanded
The Cure For Lymphoma Foundation, New York, has added six scientists to its Scientific Advisory Board. The new members are:
Michael L. Cleary, M.D., professor, Department of Pathology, Stanford University School of Medicine; Morton Coleman, M.D., clinical professor of medicine, Weill Medical College of Cornell University; Steven T. Rosen, M.D., director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University; Joseph V. Simone, M.D., senior clinical director, Huntsman Cancer Institute; Julie M. Vose, M.D., professor of medicine, Hematology/Oncology Section, University of Nebraska Medical Center; and Andrew D. Zelenetz, M.D., chief, Lymphoma Service, Memorial-Sloan Kettering Cancer Center.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||